Investor Presentaiton
Anticipated Milestones in 2021 (to Early 2022)
5
5
9
7
Multiple
Multiple
Capacity
Commercial
portfolio
•
TYVYTⓇ
•
BYVASDAⓇ
•
SULINNOⓇ
.
HALPRYZAⓇ
.
IBI-375 (Taiwan)
Potential NDA Potential NDA
•
approvals
TYVYTⓇ
-
(1L sq NSCLC)
-
(1L HCC)
-
(2L sqNSCLC)
•
BYVASDA
(1L HCC)
IBI-375
(2L mCCA, Taiwan)
•
acceptance
TYVYTⓇ
-
(1L ESCC)
(2L EGFR+NSCLC)
(1L GC)
(NSCLC, US BLA)
IBI-375 (FGFR)
(2L mCCA, mainland
China)
IBI-375 (FGFR)
(2L MCCA, Hong Kong)
•
IBI-376 (PI3K8)
•
(r/r FL)
BYVASDAⓇ
(Indonesia NDA)
IBI-326 (BCMA CART)
-
(r/r MM)
Pivotal trial
data release
/ readout
• TYVYTⓇ
(2L sqNSCLC)
Prioritized
clinical assets
Early data
readout
Capacity
expansion
Complete
construction of
36,000L
production lines
Increase total
production
capacity from
24,000L to 60,000L
•
Phase 3 ongoing
•
IBI-310 (CTLA-4)
IBI-310 (CTLA-4)
•
-
(1L ESCC)
-
IBI-306 (PCSK9)
IBI-362 (OXM3)
-
(1L GC)1
Plan to start Phase 3
•
IBI-302
-
(2L EGFR+ NSCLC)
-
IBI-375 (FGFR)
(VEGF/compliment)
-
IBI-376 (PI3KS)
•
IBI-188 (CD47)
.
IBI-318 (PD-1/PD-L1)
.
Plan to start Phase 2
•
IBI-322 (PD-L1/CD47)★
•
IBI-110 (LAG-3)★
•
IBI-939 (TIGIT)⭑
IBI-375 (FGFR)
2L MCCA
•
IBI-376 (PI3KS)
•
r/r FL
IBI-306 (PCSK9)
HeFH1
IBI-362 (OXM3)
IBI-302
(VEGF/compliment)
Phase 1 ongoing
-
IBI-322 (PD-L1/CD47)
•
IBI-110 (LAG-3)
IBI-939 (TIGIT)
IBI-315 (PD-1/HER2)
By end of 2021, we expect to have five commercial products and diverse clinical stage assets that drive long-term
upside potentials.
Innovent
Note: 1) Expect data read out for TYVYT in 1L GC and for IBI-306 in HeFH in 2021
Confidential
Copyright©2021 Innovent Biologics
7View entire presentation